Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 3/20 | 0.39 |
| ▸ | IKBKB | O14920 | 4/20 | 0.38 |
| ▸ | CHUK | O15111 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | MAP3K8 | P41279 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.33 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8832272 | 0.90 | CHEK1 (0.39) | CHEK1CYP1A2CYP2C9CYP2C19ACHE | |
| SCHEMBL14038886 | 0.90 | JAK2 (0.39) | CHEK1IKBKBMAP3K8JAK2HDAC6 | |
| SCHEMBL8827320 | 0.90 | CHEK1 (0.49) | CHEK1IKBKBACHEMAP3K8MEN1 | |
| SCHEMBL8834591 | 0.83 | IKBKB (0.39) | CHEK1IKBKBCHUKCYP1A2CYP3A4 | |
| SCHEMBL12948558 | 0.82 | CHEK1 (0.39) | CHEK1IKBKBCHUKCYP1A2CYP3A4 | |
| SCHEMBL12921997 | 0.81 | GRM2 (0.47) | CHEK1IKBKBCHUKCYP1A2CYP3A4 | |
| SCHEMBL14038891 | 0.79 | JAK2 (0.45) | MAP3K8JAK2NPC1MAPTRAB9A | |
| SCHEMBL13615175 | 0.78 | JAK2 (0.36) | CHEK1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL12922014 | 0.78 | CHEK1 (0.40) | CHEK1CYP1A2CYP2C9CYP2C19ACHE | |
| SCHEMBL1496092 | 0.78 | CHEK1 (0.47) | CHEK1IKBKBCHUKCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115038440-A | Combination cancer therapy with CHK inhibitors | 上海华禹生物科技有限公司 | 2022-09-09 | — | — | CN | claimed |
| CN-115038439-A | Combination cancer therapy with CHK inhibitors | 上海华禹生物科技有限公司 | 2022-09-09 | — | — | CN | claimed |
| CN-101481380-B | Thiofuran pyridazine compound, preparation thereof, pharmaceutical composition and uses thereof | ZHEJIANG MED XINCHANG PHARM | 2012-10-17 | — | — | CN | claimed |
| CN-101481380-A | Thiofuran pyridazine compound, preparation thereof, pharmaceutical composition and uses thereof | ZHEJIANG MEDICINE CO LTD (CN) | 2009-07-15 | — | — | CN | claimed |
| CN-115038440-A | Combination cancer therapy with CHK inhibitors | 上海华禹生物科技有限公司 | 2022-09-09 | — | — | CN | disclosed |
| CN-115038439-A | Combination cancer therapy with CHK inhibitors | 上海华禹生物科技有限公司 | 2022-09-09 | — | — | CN | disclosed |
| US-9249154-B2 | Compounds and therapeutic use thereof for protein kinase inhibition | WU ZHANGGUI (US) | 2016-02-02 | — | — | US | disclosed |
| US-8962626-B2 | Thienopyridazine compounds, their preparations, pharmaceutical compositions and uses | ZHEJIANG MEDICINE CO., LTD. XINCHANG PHARMACEUTICAL FACTORY (CN) | 2015-02-24 | — | — | US | disclosed |
| US-8962626-B2 | Thienopyridazine compounds, their preparations, pharmaceutical compositions and uses | ZHEJIANG MEDICINE CO., LTD. XINCHANG PHARMACEUTICAL FACTORY (CN) | 2015-02-24 | — | — | US | disclosed |
| US-20130143887-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | WU ZHANGGUI (US) | 2013-06-06 | — | — | US | disclosed |
| CN-101481380-B | Thiofuran pyridazine compound, preparation thereof, pharmaceutical composition and uses thereof | ZHEJIANG MED XINCHANG PHARM | 2012-10-17 | — | — | CN | disclosed |
| EP-2241569-B1 | THIENOPYRIDAZINE COMPOUNDS, THEIR PREPARATIONS, PHARMACEUTICAL COMPOSITIONS AND USES | ZHEJIANG MED XINCHANG PHARM (CN) | 2012-05-23 | — | — | EP | disclosed |
| US-20110009415-A1 | Thienopyridazine Compounds, Their Preparations, Pharmaceutical Compositions And Uses | WU, ZHANGGUI (CN) | 2011-01-13 | — | — | US | disclosed |
| US-20110009415-A1 | Thienopyridazine Compounds, Their Preparations, Pharmaceutical Compositions And Uses | WU, ZHANGGUI (CN) | 2011-01-13 | — | — | US | disclosed |
| EP-2241569-A1 | THIENOPYRIDAZINE COMPOUNDS, THEIR PREPARATIONS, PHARMACEUTICAL COMPOSITIONS AND USES | Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory (CN) | 2010-10-20 | — | — | EP | disclosed |
| CN-101481380-A | Thiofuran pyridazine compound, preparation thereof, pharmaceutical composition and uses thereof | ZHEJIANG MEDICINE CO LTD (CN) | 2009-07-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009415-A1 | Thienopyridazine Compounds, Their Preparations, Pharmaceutical Compositions And Uses | CYP3A5, ABCC5, DPYD | CHEK1 2344/4885IKBKB 2148/4885CHUK 791/4885 |
| US-20130143887-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | CHEK2, CHEK1, PLK1 | CHEK1 2/4885IKBKB 704/4885CHUK 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.